Macitentan: A Review of Its Use in Patients with Pulmonary Arterial Hypertension
- 655 Downloads
Macitentan (Opsumit®) is an orally active, dual endothelin receptor antagonist (ERA) with tissue targeting properties. Macitentan was approved recently in the EU (as monotherapy or combination therapy) for the long-term treatment of pulmonary arterial hypertension (PAH) in adults of WHO functional class II or III, and in the USA for the treatment of PAH (WHO group I) to delay disease progression and reduce hospitalization for PAH. This article reviews the pharmacological properties, efficacy and tolerability data relevant to the use of macitentan in this indication. Treatment with macitentan 10 mg once daily significantly reduced the risk for the primary composite endpoint of morbidity and mortality in patients with PAH (mostly WHO functional class II or III) in the large, randomized, placebo-controlled SERAPHIN study. Other efficacy outcomes, including exercise capacity, haemodynamic parameters and health-related quality of life also improved significantly with macitentan relative to placebo. Macitentan was generally well tolerated in this study. As with other ERAs, haemoglobin levels decreased with macitentan therapy; however, these were not progressive and stabilized following longer-term treatment. Although comparative studies are needed to definitively position macitentan with respect to other approved agents, current evidence suggests that macitentan is a useful treatment option for initial therapy in patients with WHO functional class II or III PAH, which has the potential advantage of once-daily administration.
KeywordsPulmonary Arterial Hypertension Idiopathic Pulmonary Fibrosis Functional Class Bosentan PDE5 Inhibitor
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Sohita Dhillon is a salaried employee of Adis/Springer.
- 1.Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–537.PubMedCrossRefGoogle Scholar
- 16.European Medicines Agency. Opsumit (macitentan): summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002697/WC500160899.pdf. Accessed 16 June 2014.
- 17.Actelion Pharmaceuticals US Inc. Opsumit (macitentan): US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204410s000lbl.pdf. Accessed 16 June 2014.
- 19.US Center for Drug Evaluation and Reasearch. Macitentan: pharmacology review(s). 2013. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204410Orig1s000PharmR.pdf. Accessed 16 June 2014.
- 24.Iglarz M, Landskroner K, Rey M, et al. Optimization of tissue targeting properties of macitentan, a new endothelin receptor antagonist, improves its efficacy in a model of pulmonary fibrosis associated with pulmonary arterial hypertension [abstract no. P2506]. Eur Heart J. 2011;32(Suppl 1):434.Google Scholar
- 27.US Center for Drug Evaluation and Reasearch. Macitentan: clinical pharmacology and biopharmaceutics review(s). 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204410Orig1s000ClinPharmR.pdf. Accessed 16 June 2014.
- 28.Zisowsky J, Sidharta PN, Krause A, et al. Pharmacokinetic/pharmacodynamic analyses in SERAPHIN, a randomized, controlled study of macitentan in patients with pulmonary arterial hypertension [abstract no. 1709290]. Clin Pharmacol Drug Dev. 2013;2(Suppl 1):29.Google Scholar
- 36.Sidharta P, van Giersbergen P, Wolzt M, et al. Lack of clinically relevant pharmacokinetic interactions between the dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects [abstract]. Am J Respir Crit Care Med. 2012;185:A4802.Google Scholar
- 39.Jansa P, Channick R, Delcroix M, et al. Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): results from a long-term randomised controlled trial [abstract no. P4075]. Eur Respir J. 2013;42(Suppl 57):862s.Google Scholar
- 40.Sitbon O, Channick R, Delcroix M, et al. Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) [abstract no. P4060]. Eur Respir J. 2013;42(Suppl 57):858s.Google Scholar
- 41.Mehta S, Delcroix M, Galie N. Macitentan reduced all-cause hospitalization in patients with pulmonary arterial hypertension: data from the randomized controlled SERAPHIN trial [abstract no. A2458]. In: American Thoracic Society proceedings; 16–21 May 2014; San Diego.Google Scholar
- 42.Channick R, Delcroix M, Galie N, et al. The effect of macitentan on long-term outcomes in patients with pulmonary arterial hypertension by WHO functional class: data from the randomized controlled SERAPHIN study [abstract no. A4783]. In: American Thoracic Society proceedings; 16–21 May 2014; San Diego.Google Scholar
- 43.Simonneau G, Channick R, Delcroix M, et al. Effect of macitentan on long-term outcomes in patients with pulmonary arterial hypertension (PAH): subanalysis of SERAPHIN comparing incident and prevalent patient populations not treated with background PAH-specific therapy [abstract]. Chest. 2013;144(4 Meeting abstracts):876A.CrossRefGoogle Scholar
- 44.European Medicines Agency. Assessment report: Opsumit (macitentan). 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002697/WC500160900.pdf. Accessed 16 June 2014.
- 45.McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association [erratum appears in Circulation. 2009;120:e13. Circulation. 2009;119(16):2250–94.PubMedCrossRefGoogle Scholar
- 48.European Medicines Agency. Volibris (ambrisentan): summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000839/WC500053065.pdf. Accessed 16 June 2014.
- 49.European Medicines Agency. Tracleer (bosentan): summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000401/WC500041597.pdf. Accessed 16 June 2014.
- 51.Lepist E-I, Gillies H, Smith W, et al. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes. PLoS One. 2014;9(1):e87548.PubMedCentralPubMedCrossRefGoogle Scholar
- 54.Actelion. Update on the DUAL program in digital ulcers in systemic sclerosis [media release]. 02 Dec 2013. http://www1.actelion.com/en/our-company/news-and-events/index.page?newsId=1746886.
- 57.Abe K, Kunita M, Hirooka Y, et al. Long-term treatment with novel endothelin receptor antagonist macitentan markedly attenuated severe pulmonary hypertension with angioproliferative occlusive lesions in rats [abstract]. Am J Respir Crit Care Med. 2013;187:A4632.Google Scholar
- 58.Sidharta PN, Lindegger N, Reseski K, et al. Macitentan, a novel dual endothelin receptor antagonist, does not prolong the QT/QTc interval in a thorough QTc study in healthy subjects [abstract no. PIII-61]. Clin Pharmacol Ther. 2013;93(Suppl 1):S108–9.Google Scholar